| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| General & administrative | 273,853 | 57,658 | ||
| Research & development | 677,474 | - | ||
| Total operating expenses | 951,327 | 57,658 | ||
| Loss from operations | -951,327 | -57,658 | ||
| Interest expense | 4,090 | 3,091 | ||
| Other income | 1,358 | 403 | ||
| Net loss | -954,059 | -60,346 | ||
| Net loss per common share basic | -0.04 | 0 | ||
| Net loss per common share diluted | -0.04 | 0 | ||
| Weighted average number of common shares outstanding basic | 25,599,673 | 24,000,000 | ||
| Weighted average number of common shares outstanding diluted | 25,599,673 | 24,000,000 | ||
Curanex Pharmaceuticals Inc (CURX)
Curanex Pharmaceuticals Inc (CURX)